"Adrz heeft 3 locaties in Zeeland. In Goes leveren wij acute en complexe zorg, in Vlissingen en Zierikzee poliklinische zorg. We bieden de Zeeuwse patiënt maximaal kwaliteit, veiligheid en comfort op medisch gebied van huisarts tot (super)specialistische zorg, waar en wanneer mogelijk."

During the past decade, Admiraal de Ruyter Ziekenhuis conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 8 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 4 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Admiraal de Ruyter Ziekenhuis" #1 sponsor was "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 4 trials, followed by "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 2 trials sponsored, "Amgen" with 2 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored and "Dutch Colorectal Cancer Group" with 2 trials sponsored. Other sponsors include 27 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Admiraal de Ruyter Ziekenhuis" #1 collaborator was "Netherlands Heart Foundation" with 3 trials as a collaborator, "Amsterdam UMC, location VUmc" with 2 trials as a collaborator, "Bayer" with 2 trials as a collaborator, "Catharina Ziekenhuis Eindhoven" with 2 trials as a collaborator and "Maasstad Hospital" with 2 trials as a collaborator. Other collaborators include 94 different institutions and companies that were collaborators in the rest 100 trials.

According to Clinical.Site data, the most researched conditions in "Admiraal de Ruyter Ziekenhuis" are "Atherosclerotic Cardiovascular Disease" (3 trials), "Atrial Fibrillation" (3 trials), "Appendicitis" (2 trials), "Colorectal Cancer" (2 trials) and "Familial Hypercholesterolemia" (2 trials). Many other conditions were trialed in "Admiraal de Ruyter Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Admiraal de Ruyter Ziekenhuis" are "Drug" (29 trials), "Other" (10 trials), "Procedure" (4 trials), "Device" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Evolocumab" (2 trials), "1 or 2 cycle(s) HDM (High Dose Melphalan)" (1 trials), "2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)" (1 trials) and "5-fluorouracil" (1 trials). Other intervention names were less common.

The vast majority of trials in "Admiraal de Ruyter Ziekenhuis" are 42 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Admiraal de Ruyter Ziekenhuis". 1 are not yet recruiting, 11 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 20 completed trials in Admiraal de Ruyter Ziekenhuis, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Admiraal de Ruyter Ziekenhuis, 1 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 8 trials that are defined as “Not Applicable".